Depression and anxiety can worsen psoriatic arthritis symptoms and may be overlooked, highlighting the need for comprehensive ...

Researchers examined the effect of biologic therapy use on incident psoriatic arthritis among patients with psoriasis.

Lifestyle risk factors, particularly obesity and smoking, contribute to elevated disease activity in psoriatic arthritis.

Psoriasis isn't always just a skin condition. Experts explain how it can progress to psoriatic arthritis, the warning signs ...

Weight loss after a psoriasis diagnosis lowers the risk of developing psoriatic arthritis and keeping weight off matters, but ...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with ...

A deeper understanding of the inflammatory processes driving psoriasis and psoriatic arthritis is translating into new research approaches that could potentially benefit patients. Psoriasis is a ...

The FDA expands approval of Skyrizi (risankizumab-rzaa) for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis.

From recognizing the early signs to building healthier everyday habits, explore expert-backed guidance for managing psoriasis ...

Using the card, Gruber usually met that maximum by February, leaving his health insurance to fully cover his in-network ...

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval ...

USA: A large analysis of hundreds of thousands of patient records has found that newer antidiabetic drug classes are ...